8-K
Orthofix Medical Inc. (OFIX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2021
ORTHOFIX MEDICAL INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 0-19961 | 98-1340767 |
|---|---|---|
| (State or other jurisdiction<br><br><br>of incorporation) | (Commission<br><br><br>File Number) | (IRS Employer<br><br><br>Identification No.) |
| 3451 Plano Parkway<br><br><br>Lewisville, Texas | 75056 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (214) 937-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, $0.10 par value per share | OFIX | Nasdaq Global Select Market |
| Item 2.02. | Results of Operations and Financial Condition. | |
| --- | --- |
On November 5, 2021, Orthofix Medical Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the third quarter ended September 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto.
The information furnished in this Item 2.02, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 2.02 of this report.
| Item 7.01 | Regulation FD Disclosure. |
|---|
The press release furnished in Exhibit 99.1 also provides an update on the Company’s business outlook, that is intended to be within the safe harbor provided by the Private Securities Litigation Reform Act of 1995 (the “Act”) as comprising forward looking statements within the meaning of the Act.
The information furnished in this Item 7.01, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act, or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 7.01 of this report.
| Item 9.01. | Financial Statements and Exhibits. |
|---|
(d)Exhibits
| 99.1 | Press release, dated November 5, 2021. |
|---|---|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Orthofix Medical Inc. | |
|---|---|
| By: | /s/ Kimberley A. Elting |
| Kimberley A. Elting<br><br><br>Chief Legal and Development Officer |
Date: November 5, 2021
ofix-ex991_6.htm
Exhibit 99.1
Orthofix Reports Third Quarter 2021 Results
| • | Net sales of $112 million, an increase of 1.3% over the prior year period |
|---|---|
| • | Double-digit growth over the prior year period for both global Spinal Implants and Orthopedics |
| --- | --- |
| • | More than 1,000 U.S. surgeons trained and 60,000 M6-C artificial cervical discs implanted worldwide to date |
| --- | --- |
| • | Launched Opus Mg Set synthetic bone void filler |
| --- | --- |
| • | Submitted AccelStim PMA application for the healing of fresh fractures |
| --- | --- |
LEWISVILLE, Texas — November 5, 2021— Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2021. Net sales were $112 million, earnings per share (“EPS”) was $(0.11), and adjusted EPS was $0.10.
“I am proud of the tenacity of our team as they continue to implement our strategic initiatives despite the ongoing challenges of COVID, delivering double-digit growth in both our global Spinal Implants and Orthopedics businesses,” said Orthofix President and Chief Executive Officer Jon Serbousek. “New products remain a growth driver in the business. The strong adoption of the M6-C™ artificial cervical disc continues as we recently passed the 60,000 worldwide implant mark, and sales of our FITBONE™ limb-lengthening system have accelerated throughout the year, resulting in third quarter revenue growing 30 percent sequentially.”
“As we close out the year, we will be focused on driving top-line performance and exiting the year with mid-single digit growth. We expect this accelerated growth in the near term to come from the continued strength of the M6-C disc, the FITBONE system, and our recently bolstered 3D-printed titanium spinal interbody portfolio,” continued Serbousek. “Over the long term, we have multiple initiatives in place, including diversification of our biologics portfolio with products like Opus™ Mg Set synthetic bone void filler and the planned expansion of our bone growth therapy portfolio with the AccelStim™ ultrasound bone healing therapy for the healing of fresh and nonunion fractures. We anticipate the recent PMA application will allow us to bring this innovative offering and new indication to market in 2022.”
Financial Results Overview
The following table provides net sales by major product category by reporting segment:
| Three Months Ended September 30, | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Unaudited, U.S. Dollars, in thousands) | 2021 | 2020 | Change | Constant<br><br><br>Currency<br><br><br>Change | ||||||
| Bone Growth Therapies | $ | 45,168 | $ | 47,066 | (4.0 | %) | (4.0 | %) | ||
| Spinal Implants | 28,151 | 25,505 | 10.4 | % | 10.2 | % | ||||
| Biologics | 12,806 | 15,245 | (16.0 | %) | (16.0 | %) | ||||
| Global Spine | 86,125 | 87,816 | (1.9 | %) | (2.0 | %) | ||||
| Global Orthopedics | 26,303 | 23,169 | 13.5 | % | 12.2 | % | ||||
| Net sales | $ | 112,428 | $ | 110,985 | 1.3 | % | 1.0 | % |
Gross profit decreased $0.6 million to $84.1 million. Gross margin decreased to 74.8% compared to 76.4% in the prior year period.
Net loss was $(2.2) million, or $(0.11) per share, compared to net income of $4.7 million, or $0.24 per share in the prior year period. Adjusted net income was $2.0 million, or $0.10 per share, compared to adjusted net income of $6.0 million, or $0.31 per share in the prior year period.
EBITDA was $5.0 million, compared to $15.0 million in the prior year period. Adjusted EBITDA was $11.9 million, or 10.6% of net sales, compared to $19.7 million, or 17.8% of net sales, in the prior year period.
Liquidity
As of September 30, 2021, cash, cash equivalents, and restricted cash totaled $83.2 million compared to $96.8 million as of December 31, 2020. As of September 30, 2021, the Company had no borrowings under its five year $300 million secured revolving credit facility. Cash flow from operations decreased $45.3 million to $6.7 million, while free cash flow decreased $45.4 million to
$(6.1) million. This decrease in cash was primarily attributable to the timing and repayment of certain funds received under the CARES Act and from a $15.0 million milestone payment made in 2021 based upon our M6-C artificial cervical disc sales volumes.
Business Outlook
The Company continues to monitor and evaluate the impact the global response to the COVID-19 pandemic has had, and will continue to have, on its operations and financial results. As of the date hereof, the Company expects the following net sales results for the year ended December 31, 2021. These projections also include the impact of any expected changes in foreign currency exchange rates.
| Current 2021 Outlook | Previous 2021 Outlook | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Unaudited, U.S. Dollars, in millions, except per share data) | Low | High | Low | High | ||||||
| Net sales | $ | 460.0 | ^1^ | $ | 464.0 | ^1^ | $ | 468.0 | $ | 474.0 |
| Adjusted EBITDA | $ | 57.0 | ^2^ | $ | 58.0 | ^2^ | $ | 58.0 | $ | 61.0 |
| Adjusted EPS | $ | 0.71 | ^3^ | $ | 0.75 | ^3^ | $ | 0.74 | $ | 0.82 |
^1^^^Represents a year-over-year increase of 13.1% to 14.1% on a reported basis
^2^^^Represents a year-over-year increase of 19.7% to 21.8%
^3^^^Represents a year-over-year increase of 173.1% to 188.5%
The Company does not provide U.S. GAAP financial measures, other than net sales, on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, accounting fair value adjustments, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with U.S. GAAP.
Conference Call
Orthofix will host a conference call today at 8:30 AM Eastern time to discuss the Company's financial results for the third quarter of 2021. Interested parties may access the conference call by dialing (833) 670-0709 in the U.S. and (343) 761-2533 outside the U.S., and referencing the conference ID 1889020. A replay of the call will be available for three weeks by dialing (800) 585-8367 in the U.S. or (416) 621-4642 outside the U.S., and entering the conference ID 1889020. A webcast of the conference call may be accessed at ir.Orthofix.com.
About Orthofix
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The Company’s mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries via the Company's sales representatives and distributors. For more information, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”). Factors that could cause or contribute to such differences may include, but are not limited to, (i) risks relating to the effects of the COVID-19 pandemic on our business, including (A) surgeries that use our products being delayed or cancelled as a result of hospitals and surgery centers being closed or limited to life-threatening and/or essential procedures, (B) portions of our global workforce being unable to work fully and/or effectively due to illness, quarantines, government actions (including "shelter in place" orders or advisories), facility closures or other reasons related to the pandemic, (C) disruptions to our supply chain, (D) customers and payors being unable to satisfy contractual obligations to us, including the ability to make timely payment for purchases, (E) general economic weakness in markets in which we operate affecting customer spending, and (F) other unpredictable aspects of the pandemic; (ii) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities; (iii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iv) development and acceptance of new products or product
enhancements, (v) clinical and statistical verification of the benefits achieved via the use of our products, (vi) our ability to adequately manage inventory, (vii) our ability to recruit and retain management and key personnel, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). To the extent that the COVID-19 pandemic continues to adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in Part I, Item 1A under the heading Risk Factors in our 2020 Form 10-K, such as our ability to generate sufficient cash flows to run our business and our ability to protect our information technology networks and infrastructure from unauthorized access, misuse, malware, phishing and other events that could have a security impact as a result of our remote working environment or otherwise. As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.
This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.
| Company Contact |
|---|
| Orthofix Medical Inc. |
| Alexa Huerta |
| P: 214-937-3190 |
| E: alexahuerta@orthofix.com |
ORTHOFIX MEDICAL INC.
Condensed Consolidated Statements of Operations
| Three Months Ended | Nine Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| September 30, | September 30, | |||||||||||
| (U.S. Dollars, in thousands, except share and per share data) | 2021 | 2020 | 2021 | 2020 | ||||||||
| (unaudited) | ||||||||||||
| Net sales | $ | 112,428 | $ | 110,985 | $ | 339,415 | $ | 288,943 | ||||
| Cost of sales | 28,307 | 26,243 | 81,660 | 72,818 | ||||||||
| Gross profit | 84,121 | 84,742 | 257,755 | 216,125 | ||||||||
| Sales and marketing | 56,097 | 52,926 | 164,220 | 150,718 | ||||||||
| General and administrative | 16,312 | 16,541 | 51,091 | 49,453 | ||||||||
| Research and development | 12,360 | 9,962 | 36,378 | 28,691 | ||||||||
| Acquisition-related amortization and remeasurement | (335 | ) | 1,138 | 5,028 | (2,766 | ) | ||||||
| Operating income (loss) | (313 | ) | 4,175 | 1,038 | (9,971 | ) | ||||||
| Interest expense, net | (433 | ) | (731 | ) | (1,400 | ) | (2,055 | ) | ||||
| Other income (expense), net | (1,789 | ) | 1,817 | (3,528 | ) | 6,088 | ||||||
| Income (loss) before income taxes | (2,535 | ) | 5,261 | (3,890 | ) | (5,938 | ) | |||||
| Income tax benefit (expense) | 364 | (607 | ) | (1,677 | ) | 17,833 | ||||||
| Net income (loss) | $ | (2,171 | ) | $ | 4,654 | $ | (5,567 | ) | $ | 11,895 | ||
| Net income (loss) per common share: | ||||||||||||
| Basic | $ | (0.11 | ) | $ | 0.24 | $ | (0.28 | ) | $ | 0.62 | ||
| Diluted | (0.11 | ) | 0.24 | (0.28 | ) | 0.61 | ||||||
| Weighted average number of common shares: | ||||||||||||
| Basic | 19,769,823 | 19,335,718 | 19,633,782 | 19,217,057 | ||||||||
| Diluted | 19,769,823 | 19,398,567 | 19,633,782 | 19,319,302 |
ORTHOFIX MEDICAL INC.
Condensed Consolidated Balance Sheets
| (U.S. Dollars, in thousands, except share data) | December 31,<br><br><br>2020 | ||
|---|---|---|---|
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | 82,710 | $ | 96,291 |
| Restricted cash | 505 | 530 | |
| Accounts receivable, net of allowances of 4,928 and 4,848, respectively | 68,971 | 72,423 | |
| Inventories | 84,678 | 84,635 | |
| Prepaid expenses and other current assets | 23,348 | 16,500 | |
| Total current assets | 260,212 | 270,379 | |
| Property, plant and equipment, net | 58,784 | 63,613 | |
| Intangible assets, net | 54,794 | 60,517 | |
| Goodwill | 83,357 | 84,018 | |
| Deferred income taxes | 22,745 | 25,042 | |
| Other long-term assets | 20,503 | 22,292 | |
| Total assets | 500,395 | $ | 525,861 |
| Liabilities and shareholders’ equity | |||
| Current liabilities | |||
| Accounts payable | 19,437 | $ | 23,118 |
| Current portion of finance lease liability | 2,570 | 510 | |
| Other current liabilities | 57,997 | 80,271 | |
| Total current liabilities | 80,004 | 103,899 | |
| Long-term portion of finance lease liability | 20,044 | 22,338 | |
| Other long-term liabilities | 35,514 | 42,760 | |
| Total liabilities | 135,562 | 168,997 | |
| Contingencies | |||
| Shareholders’ equity | |||
| Common shares 0.10 par value; 50,000,000 shares authorized;<br> 19,741,410 and 19,423,874 issued and outstanding as of September 30,<br> 2021 and December 31, 2020, respectively | 1,974 | 1,942 | |
| Additional paid-in capital | 307,783 | 292,291 | |
| Retained earnings | 53,812 | 59,379 | |
| Accumulated other comprehensive income | 1,264 | 3,252 | |
| Total shareholders’ equity | 364,833 | 356,864 | |
| Total liabilities and shareholders’ equity | 500,395 | $ | 525,861 |
All values are in US Dollars.
ORTHOFIX MEDICAL INC. Non-GAAP Financial Measures
The following tables present reconciliations of operating income (loss), net income (loss), EPS, and net cash from operating activities, in each case calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to, as applicable, non-GAAP financial measures, referred to as "EBITDA," "Adjusted EBITDA," "Adjusted net income (loss)," "Adjusted EPS," and "Free cash flow" that exclude items specified in the tables. A more detailed explanation of the items excluded from these non-GAAP financial measures, as well as why management believes the non-GAAP financial measures are useful to them, is included following the reconciliations.
EBITDA and Adjusted EBITDA
| Three Months Ended September 30, 2021 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Unaudited, U.S. Dollars, in thousands) | Global Spine | Global Orthopedics | Corporate | Total Orthofix | ||||||||
| Operating income (loss) | $ | 10,042 | $ | (976 | ) | $ | (9,379 | ) | $ | (313 | ) | |
| Other income (expense), net | (420 | ) | (1,231 | ) | (138 | ) | (1,789 | ) | ||||
| Depreciation and amortization | 2,501 | 1,571 | 854 | 4,926 | ||||||||
| Amortization of acquired intangibles | 1,785 | 440 | — | 2,225 | ||||||||
| EBITDA | $ | 13,908 | $ | (196 | ) | $ | (8,663 | ) | $ | 5,049 | ||
| Share-based compensation expense | 1,590 | 490 | 1,759 | 3,839 | ||||||||
| Foreign exchange impact | 426 | 1,013 | 134 | 1,573 | ||||||||
| Strategic investments | 242 | 319 | 761 | 1,322 | ||||||||
| Acquisition-related fair value adjustments | (2,300 | ) | — | — | (2,300 | ) | ||||||
| Legal judgments/settlements | 443 | (765 | ) | 1 | (321 | ) | ||||||
| Succession and transition charges | 30 | — | (9 | ) | 21 | |||||||
| Medical device regulation | 640 | 501 | 971 | 2,112 | ||||||||
| Business interruption - COVID-19 | 567 | 10 | 8 | 585 | ||||||||
| Adjusted EBITDA | $ | 15,546 | $ | 1,372 | $ | (5,038 | ) | $ | 11,880 | |||
| Nine Months Ended September 30, 2021 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (Unaudited, U.S. Dollars, in thousands) | Global Spine | Global Orthopedics | Corporate | Total Orthofix | ||||||||
| Operating income (loss) | $ | 32,366 | $ | (4,875 | ) | $ | (26,453 | ) | $ | 1,038 | ||
| Other income (expense), net | (638 | ) | (2,024 | ) | (866 | ) | (3,528 | ) | ||||
| Depreciation and amortization | 7,754 | 4,906 | 2,797 | 15,457 | ||||||||
| Amortization of acquired intangibles | 5,353 | 1,343 | — | 6,696 | ||||||||
| EBITDA | $ | 44,835 | $ | (650 | ) | $ | (24,522 | ) | $ | 19,663 | ||
| Share-based compensation expense | 4,716 | 1,622 | 5,122 | 11,460 | ||||||||
| Foreign exchange impact | 672 | 1,639 | 863 | 3,174 | ||||||||
| Strategic investments | 394 | 2,053 | 1,436 | 3,883 | ||||||||
| Acquisition-related fair value adjustments | (450 | ) | — | (375 | ) | (825 | ) | |||||
| Legal judgments/settlements | 393 | (660 | ) | (52 | ) | (319 | ) | |||||
| Succession and transition charges | 452 | 62 | 150 | 664 | ||||||||
| Medical device regulation | 1,745 | 1,567 | 2,611 | 5,923 | ||||||||
| Business interruption - COVID-19 | 573 | 26 | 33 | 632 | ||||||||
| Adjusted EBITDA | $ | 53,330 | $ | 5,659 | $ | (14,734 | ) | $ | 44,255 | |||
| Three Months Ended September 30, 2020 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (Unaudited, U.S. Dollars, in thousands) | Global Spine | Global Orthopedics | Corporate | Total Orthofix | ||||||||
| Operating income (loss) | $ | 13,247 | $ | (1,687 | ) | $ | (7,385 | ) | $ | 4,175 | ||
| Other income (expense), net | 610 | 1,077 | 130 | 1,817 | ||||||||
| Depreciation and amortization | 4,445 | 1,434 | 1,059 | 6,938 | ||||||||
| Amortization of acquired intangibles | 1,658 | 434 | — | 2,092 | ||||||||
| EBITDA | $ | 19,960 | $ | 1,258 | $ | (6,196 | ) | $ | 15,022 | |||
| Share-based compensation expense | 1,494 | 423 | 1,925 | 3,842 | ||||||||
| Foreign exchange impact | (626 | ) | (1,125 | ) | (132 | ) | (1,883 | ) | ||||
| Strategic investments | 15 | 217 | 642 | 874 | ||||||||
| Acquisition-related fair value adjustments | (700 | ) | 52 | — | (648 | ) | ||||||
| Loss on investment securities | — | — | — | — | ||||||||
| Legal judgments/settlements | 32 | 267 | (1 | ) | 298 | |||||||
| Succession and transition charges | 941 | 304 | 78 | 1,323 | ||||||||
| Medical device regulation | 22 | 204 | 488 | 714 | ||||||||
| Business interruption - COVID-19 | 48 | 43 | 89 | 180 | ||||||||
| Adjusted EBITDA | $ | 21,186 | $ | 1,643 | $ | (3,107 | ) | $ | 19,722 | |||
| Nine Months Ended September 30, 2020 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (Unaudited, U.S. Dollars, in thousands) | Global Spine | Global Orthopedics | Corporate | Total Orthofix | ||||||||
| Operating income (loss) | $ | 23,879 | $ | (9,766 | ) | $ | (24,084 | ) | $ | (9,971 | ) | |
| Other income (expense), net | 745 | 750 | 4,593 | 6,088 | ||||||||
| Depreciation and amortization | 9,560 | 4,151 | 3,232 | 16,943 | ||||||||
| Amortization of acquired intangibles | 4,486 | 870 | — | 5,356 | ||||||||
| EBITDA | $ | 38,670 | $ | (3,995 | ) | $ | (16,259 | ) | $ | 18,416 | ||
| Share-based compensation expense | 4,586 | 1,578 | 5,291 | 11,455 | ||||||||
| Foreign exchange impact | (712 | ) | (902 | ) | (161 | ) | (1,775 | ) | ||||
| Strategic investments | 30 | 473 | 1,366 | 1,869 | ||||||||
| Acquisition-related fair value adjustments | (7,600 | ) | 100 | — | (7,500 | ) | ||||||
| Loss on investment securities | — | — | 219 | 219 | ||||||||
| Legal judgments/settlements | (420 | ) | 546 | 372 | 498 | |||||||
| Succession and transition charges | 2,022 | 1,402 | 762 | 4,186 | ||||||||
| Medical device regulation | 376 | 496 | 967 | 1,839 | ||||||||
| Business interruption - COVID-19 | 389 | 308 | (4,335 | ) | (3,638 | ) | ||||||
| Adjusted EBITDA | $ | 37,341 | $ | 6 | $ | (11,778 | ) | $ | 25,569 |
Adjusted Net Income
| Three Months Ended<br><br><br>September 30, | Nine Months Ended<br><br><br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Unaudited, U.S. Dollars, in thousands) | 2021 | 2020 | 2021 | 2020 | ||||||||
| Net income (loss) | $ | (2,171 | ) | $ | 4,654 | $ | (5,567 | ) | $ | 11,895 | ||
| Foreign exchange impact | 1,573 | (1,883 | ) | 3,174 | (1,775 | ) | ||||||
| Strategic investments | 1,343 | 872 | 3,976 | 1,869 | ||||||||
| Acquisition-related fair value adjustments | (2,300 | ) | (648 | ) | (825 | ) | (7,500 | ) | ||||
| Amortization of acquired intangibles | 2,232 | 2,092 | 6,713 | 5,356 | ||||||||
| Loss on investment securities | — | — | — | 219 | ||||||||
| Legal judgments/settlements | (321 | ) | 298 | (319 | ) | 498 | ||||||
| Succession and transition charges | 21 | 1,323 | 664 | 4,186 | ||||||||
| Medical device regulation | 2,112 | 714 | 5,923 | 1,839 | ||||||||
| Business interruption - COVID-19 | 587 | 183 | 638 | (3,635 | ) | |||||||
| Long-term income tax rate adjustment | (1,096 | ) | (1,609 | ) | (2,658 | ) | (16,515 | ) | ||||
| Adjusted net income (loss) | $ | 1,980 | $ | 5,996 | $ | 11,719 | $ | (3,563 | ) |
Adjusted EPS
| Three Months Ended<br><br><br>September 30, | Nine Months Ended<br><br><br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Unaudited, per diluted share) | 2021 | 2020 | 2021 | 2020 | ||||||||
| EPS | $ | (0.11 | ) | $ | 0.24 | $ | (0.28 | ) | $ | 0.61 | ||
| Foreign exchange impact | 0.08 | (0.10 | ) | 0.16 | (0.09 | ) | ||||||
| Strategic investments | 0.07 | 0.04 | 0.20 | 0.10 | ||||||||
| Acquisition-related fair value adjustments | (0.12 | ) | (0.03 | ) | (0.04 | ) | (0.39 | ) | ||||
| Amortization of acquired intangibles | 0.11 | 0.11 | 0.34 | 0.28 | ||||||||
| Loss on investment securities | — | — | — | 0.01 | ||||||||
| Legal judgments/settlements | (0.02 | ) | 0.02 | (0.02 | ) | 0.03 | ||||||
| Succession and transition charges | — | 0.07 | 0.03 | 0.22 | ||||||||
| Medical device regulation | 0.11 | 0.04 | 0.30 | 0.10 | ||||||||
| Business interruption - COVID-19 | 0.03 | 0.01 | 0.03 | (0.19 | ) | |||||||
| Long-term income tax rate adjustment | (0.05 | ) | (0.09 | ) | (0.13 | ) | (0.87 | ) | ||||
| Adjusted EPS | $ | 0.10 | $ | 0.31 | $ | 0.59 | $ | (0.19 | ) | |||
| Weighted average number of diluted common shares (treasury stock method) | 19,975,851 | 19,405,781 | 19,945,411 | 19,217,057 |
Free Cash Flow
| Nine Months Ended<br><br><br>September 30, | ||||||
|---|---|---|---|---|---|---|
| (Unaudited, U.S. Dollars, in thousands) | 2021 | 2020 | ||||
| Net cash from operating activities | $ | 6,696 | $ | 51,981 | ||
| Capital expenditures | (12,781 | ) | (12,704 | ) | ||
| Free cash flow | $ | (6,085 | ) | $ | 39,277 |
Constant Currency
Constant currency is a non-GAAP measure, which is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.
EBITDA
EBITDA is a non-GAAP financial measure, which is calculated by adding interest income (expense), net; income tax expense (benefit); and depreciation and amortization to net income. EBITDA provides management with additional insight to its results of operations. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing our business.
Adjusted EBITDA, Adjusted Net Income and Adjusted EPS
These non-GAAP financial measures provide management with additional insight to its results of operations and are calculated using the following adjustments:
| • | Share-based compensation expense – costs related to our share-based compensation plans, which include stock options, restricted stock, market-based restricted stock awards and our stock purchase plan; see the share-based compensation footnote in our Form 10-Q for the quarter ended September 30, 2021 for an allocation of these costs by consolidated statement of income line item; note that certain share-based compensation costs are instead included within succession and transition charges for 2020 and medical device regulation for 2021 |
|---|---|
| • | Foreign exchange impact – gains and losses related to foreign currency transactions, which are recorded as other income (expense), net |
| --- | --- |
| • | Strategic investments – costs related to our strategic investments, such as due diligence and integration costs, which are primarily recorded as general and administrative expenses |
| --- | --- |
| • | Acquisition-related fair value adjustments – comprised of (i) gains and losses related to remeasurement of contingent consideration to fair value, which are recorded as operating expenses, (ii) the amortization of an adjustment made to inventory acquired to reflect the expected selling price of the acquired inventory less the cost of expected selling efforts and a reasonable profit allowance for the selling effort for finished goods inventory, which is recorded as cost of sales, and (iii) costs recognized related to acquired in-process research and development assets, which were expensed immediately. |
| --- | --- |
| • | Amortization of acquired intangibles – amortization of intangible assets acquired in business combinations or asset acquisitions, including items such as developed technologies, customer relationships, trade names, manufacturing agreements, and other intangible assets, which are recorded in cost of sales or operating expenses |
| --- | --- |
| • | Loss on investment securities – net gains or losses recognized (realized or unrealized) within other income (expense), net relating to certain of our investments |
| --- | --- |
| • | Legal judgments/settlements – adverse or favorable legal judgments or negotiated legal settlements, which are recorded as general and administrative expenses |
| --- | --- |
| • | Succession and transition charges – costs related to the transition of certain named executive officers and certain targeted restructuring costs, including any cessation and onboarding amounts, accelerated share-based compensation expense, consulting services, and other related expenses, which are primarily recorded as general and administrative expenses |
| --- | --- |
| • | Medical device regulation – incremental costs incurred (i) to establish initial compliance with the regulations set forth by the European Union Medical Device Regulation (“MDR”) and the U.S. Food and Drug Administration related to our currently-approved medical devices, which are recorded primarily as research and development expenses, and (ii) related to rationalization of certain product lines that we do not expect to continue to market subsequent to the effective date of these regulations, which are recorded primarily as costs of sales |
| --- | --- |
| • | Business interruption – COVID-19 – gains and losses related to the realized effects the COVID-19 pandemic has had on our business operations, which primarily consist of (i) incremental costs incurred to enhance the safety and sanitation of our facilities in response to COVID-19, which are primarily reported in general and administrative expenses, (ii) costs associated with the redesign of certain products in response to supply chain disruption caused by COVID-19, and (iii) inventory reserve adjustments in 2020 related to products that were set to expire, which are reflected in cost of sales |
| --- | --- |
| • | Long-term income tax rate adjustment – reflects management’s expectation of a long-term normalized effective tax rate of 27% for 2020 and 2021 results and outlook, which is based on current tax law and current expected adjusted income; actual reported tax expense will ultimately be based on GAAP earnings and may differ from the expected long-term normalized effective tax rate due to a variety of factors, including the resolutions of issues arising from tax audits with various tax authorities, the ability to realize deferred tax assets, and the tax impact of certain reconciling items that are excluded in determining Adjusted Net Income and Adjusted EPS |
| --- | --- |
Free Cash Flow
Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.
Usefulness and Limitations of Non-GAAP Financial Measures
Management uses non-GAAP measures to evaluate performance period-over-period, to analyze the underlying trends in our business, to assess performance relative to competitors and to establish operational goals and forecasts that are used in allocating resources. Management uses these non-GAAP measures as the basis for assessing the ability of the underlying operations to generate cash. In addition, management uses these non-GAAP measures to further its understanding of the performance of our business units.
Material Limitations Associated with the Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost and can have a material effect on cash flows. Similarly, certain non-cash expenses, such as share-based compensation, do not directly impact cash flows, but are part of total compensation costs accounted for under GAAP.
Compensation for Limitations Associated with Use of Non-GAAP Financial Measures
We compensate for the limitations of our non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance. The GAAP results provide the ability to understand our performance based on a defined set of criteria. The non-GAAP measures reflect the underlying operating results of our businesses, which we believe is an important measure of our overall performance. We provide a detailed reconciliation of the non-GAAP financial measures to our most directly comparable GAAP measures, and encourage investors to review this reconciliation.
Usefulness of Non-GAAP Financial Measures to Investors
We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. Management believes it is important to provide investors with the same non-GAAP metrics it uses to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to its historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.
Source
Orthofix Medical Inc.
10